Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. entered into a Collaboration Agreement to form a new limited liability company, Healthstar, with Kare Rx Hub, LLC. Wellgistics will hold a 51% membership interest and Kare Hub will hold 49%. Kare Hub will transfer specified intellectual property and related assets into Healthstar.
As consideration, Wellgistics agreed to pay Kare Pharmtech an aggregate purchase price of $2,000,000 in unregistered common stock. The agreement provides for 1,500,000 shares at closing and, at Wellgistics’ option, additional shares by April 1, 2027, based on a two-day volume-weighted average price. The Purchase Shares will be restricted, with Kare Pharmtech subject to a 12‑month lock-up from each payment date.
A related press release explains that the joint venture combines Wellgistics’ EinsteinRx™ and HubRx AI™ platforms with KareRx’s digital hub, creating an integrated ecosystem that can potentially reach more than 200,000 patient lives and support direct‑to‑patient and decentralized care models.
Wellgistics Health, Inc. filed a shelf registration to offer up to $200,000,000 of securities, including Common Stock, Preferred Stock, Debt Securities, Warrants, Rights and Units, to be sold from time to time.
The prospectus states the offering is on a shelf basis under Rule 415 and that proceeds are intended for general corporate purposes, including product development, R&D, licensing, capital expenditures and working capital. The prospectus discloses 126,653,372 shares issued and outstanding as of April 10, 2026 and a reported Nasdaq closing price of $0.1441 per share on April 14, 2026.
Wellgistics Health, Inc. director Herman Gary L filed an initial Form 3, which is a statement of his beneficial ownership of company securities. This filing does not list any stock purchases, sales, or option exercises, and instead establishes his status as an insider for future ownership reporting.
Wellgistics Health, Inc. director Eric Michael Sherb has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing reports no transactions and does not show any specific share or option holdings in the provided data.
Wellgistics Health, Inc. terminated a prior Settlement Agreement with Silverback Capital Inc. that had allowed it to issue common stock under Section 3(a)(10) of the Securities Act. Before termination, the company issued 6,866,000 shares under this structure. The agreement is no longer in effect, no additional shares will be issued under it, and Silverback has been asked to return all rights to unpaid claims to the relevant creditors. Wellgistics elected to end this settlement structure to pursue alternative strategic and financing initiatives, which the company states eliminates potential future dilution tied to the Settlement Agreement.
Wellgistics Health, Inc. entered into a Note Purchase Agreement on April 1, 2026 to issue and sell up to $1,250,000 in aggregate principal amount of promissory notes in a private offering. Investors will pay $1,000,000, reflecting a 20% original issue discount.
The Notes bear 0% interest unless an event of default occurs, in which case interest increases to 15% per year. All principal and any default interest are due on the earlier of 12 months from issuance or the closing of a Qualified Financing. While the notes are outstanding, the company has agreed not to incur additional borrowed money debt or grant new liens, and investors receive the right to participate in future securities offerings up to 100% of their note principal.
Wellgistics Health, Inc. has notified stockholders that holders of a majority of its outstanding common stock approved, by written consent, a board-authorized reverse stock split at a ratio between 1-for-25 and 1-for-200, exercisable at the Board's discretion within 12 months of the written consent.
The action was approved by holders representing 66,590,104 votes (approximately 55.32%) of the 120,380,108 shares issued and outstanding as of April 1, 2026. The company will mail this Information Statement on or about April 3, 2026. The Board may file the amendment to effect a reverse split at any time before the end of the 12-month period or decide not to proceed.
Wellgistics Health, Inc. director Marlene Velez has filed an initial Form 3, which is a required statement of her beneficial ownership position in the company’s securities. The filing shows no reported purchases, sales, option exercises, gifts, or other transactions at this time.
Wellgistics Health, Inc. approved by majority written consent a board-authorized reverse stock split in a ratio between 1-for-25 and 1-for-200, with the Board able to set the exact ratio within 12 months.
The action was approved by holders representing 66,590,104 votes (55.32%) of the 120,380,108 shares outstanding as of the Record Date. The company says the Reverse Split is intended to attempt to meet Nasdaq's $1.00 minimum bid requirement; Nasdaq compliance period expires June 8, 2026. The Information Statement will be mailed on or about April 3, 2026. Estimated mailing costs are approximately $10,000. The Board retains discretion not to effect the Reverse Split even after stockholder approval.
Wellgistics Health, Inc. approved by majority written consent an amendment authorizing a forward‑looking reverse split of its Common Stock at a ratio between 1-for-25 and 1-for-200, with the Board authorized to set the exact ratio any time within 12 months of the consent.
The approval was effected by written consent on March 23, 2026; as of that record date the company had 120,380,108 shares issued and outstanding and holders representing 66,590,104 votes (approximately 55.32%) voted in favor. The Board may file the Certificate of Amendment to effect the Reverse Split or elect not to proceed. The company received Nasdaq notice on December 10, 2025 and has a compliance period through June 8, 2026.